BMS gets EC approval for Opdivo, Yervoy combo for treatment of metastatic NSCLC
The combination of Opdivo plus Yervoy with two cycles of chemotherapy is the first dual immunotherapy-based treatment option approved for patients in the European Union (EU) with this